biote Corp. (NASDAQ:BTMD) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski – Truist Securities Jonna Kim – TD Cowen Richard Magnusen – B. Riley Securities George Kelly – ROTH Capital Kaumil Gajrawala – Jefferies Operator Good day, and welcome to the Biote Second Quarter 2024 Earnings Conference Call. All participants will ...

Exhibit 99.1 Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX – August 8, 2024 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Finan ...

Shares of biote Corp. (BTMD) have gained 14.8% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.27 indicates a potential upside of 25.4%. Price, Consensus and EPS Surprise While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets ha ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

The sharp upsurge in Biote's shares can be attributed to the company's announcement that it has signed a binding term sheet with stockholder Marci Donovitz, the ex-wife of founder Gary Donovitz, to resolve her legal claims. She claims that the blank-check company deal that took Biote public was manipulated against the founder's best interests. As part of the settlement, Biote is repurchasing Marci Donovitz's 8.3 million shares at an average price of $7.23 for an aggregate of $60 million. The stock currently ...

• our ability to retain existing key management, to integrate recent hires and to attract, retain and motivate qualified personnel; • the overall strength and stability of the economies in the markets in which we operate or intend to operate in the future; and • regulatory, legislative and political changes. Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, prospects, financial condition, and results of operations. ...

biote Corp. (NASDAQ:BTMD) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Operator Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 360%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.14, delivering a surprise of 75%.Over the last four quarters, the company has surpa ...

Procedure revenue growth and strengthened profitability drive solid financial performance IRVING, TX – May 7, 2024—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. • Revenue of $46.8 million, up 4.4% "Procedure revenue increased 6.6% in the first quarter, reflecting stable demand from established clinics within our natio ...

The market expects biote Corp. (BTMD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 7, 2024, might help the stock move higher if these key numbers are bette ...